Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Naturhouse Health

BATS-CHIXE:NTHe
Snowflake Description

Flawless balance sheet and good value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NTHe
BATS-CHIXE
€88M
Market Cap
  1. Home
  2. GB
  3. Retail
Company description

Naturhouse Health, S.A. operates in the nutrition and weight management industry in Spain and internationally. The last earnings update was 36 days ago. More info.


Add to Portfolio Compare Print
NTHe Share Price and Events
7 Day Returns
0%
BATS-CHIXE:NTHe
-0.9%
GB Specialty Retail
0.1%
GB Market
1 Year Returns
0.5%
BATS-CHIXE:NTHe
-31.7%
GB Specialty Retail
-23.6%
GB Market
NTHe Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Naturhouse Health (NTHe) 0% 0% - 0.5% -51.2% -
GB Specialty Retail -0.9% -29.3% -43.3% -31.7% -41.6% -47.1%
GB Market 0.1% -15.5% -27% -23.6% -24.3% -23.5%
1 Year Return vs Industry and Market
  • NTHe outperformed the Specialty Retail industry which returned -31.7% over the past year.
  • NTHe outperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned -23.6% over the past year.
Price Volatility
NTHe
Industry
5yr Volatility vs Market

Value

 Is Naturhouse Health undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Naturhouse Health to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Naturhouse Health.

BATS-CHIXE:NTHe Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 7.5%
Perpetual Growth Rate 10-Year GB Government Bond Rate 0.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BATS-CHIXE:NTHe
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year GB Govt Bond Rate 0.5%
Equity Risk Premium S&P Global 7.5%
Specialty Retail Unlevered Beta Simply Wall St/ S&P Global 0.83
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.834 (1 + (1- 25%) (11.82%))
0.938
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.94
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.53% + (0.938 * 7.46%)
7.53%

Discounted Cash Flow Calculation for BATS-CHIXE:NTHe using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Naturhouse Health is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

BATS-CHIXE:NTHe DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 7.53%)
2020 18.57 Est @ -1.06% 17.27
2021 18.46 Est @ -0.58% 15.97
2022 18.42 Est @ -0.25% 14.81
2023 18.41 Est @ -0.02% 13.77
2024 18.44 Est @ 0.15% 12.83
2025 18.49 Est @ 0.26% 11.96
2026 18.55 Est @ 0.34% 11.16
2027 18.63 Est @ 0.4% 10.42
2028 18.71 Est @ 0.44% 9.73
2029 18.80 Est @ 0.47% 9.09
Present value of next 10 years cash flows €127.00
BATS-CHIXE:NTHe DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= €18.80 × (1 + 0.53%) ÷ (7.53% – 0.53%)
€269.97
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €269.97 ÷ (1 + 7.53%)10
€130.63
BATS-CHIXE:NTHe Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €127.00 + €130.63
€257.63
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €257.63 / 59.95
€4.3
BATS-CHIXE:NTHe Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in BATS-CHIXE:NTHe represents 1.51701x of BME:NTH
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
1.51701x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 4.30 x 1.51701
€6.52
Value per share (EUR) From above. €6.52
Current discount Discount to share price of €2.23
= -1 x (€2.23 - €6.52) / €6.52
65.8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Naturhouse Health is available for.
Intrinsic value
>50%
Share price is €2.23 vs Future cash flow value of €6.52
Current Discount Checks
For Naturhouse Health to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Naturhouse Health's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Naturhouse Health's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Naturhouse Health's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Naturhouse Health's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BATS-CHIXE:NTHe PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in EUR €0.22
BME:NTH Share Price ** BME (2020-02-25) in EUR €1.47
United Kingdom of Great Britain and Northern Ireland Specialty Retail Industry PE Ratio Median Figure of 23 Publicly-Listed Specialty Retail Companies 7.37x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 748 Publicly-Listed Companies 12.61x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Naturhouse Health.

BATS-CHIXE:NTHe PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= BME:NTH Share Price ÷ EPS (both in EUR)

= 1.47 ÷ 0.22

6.65x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Naturhouse Health is good value based on earnings compared to the GB Specialty Retail industry average.
  • Naturhouse Health is good value based on earnings compared to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does Naturhouse Health's expected growth come at a high price?
Raw Data
BATS-CHIXE:NTHe PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 6.65x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United Kingdom of Great Britain and Northern Ireland Specialty Retail Industry PEG Ratio Median Figure of 15 Publicly-Listed Specialty Retail Companies 0.69x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 517 Publicly-Listed Companies 0.99x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Naturhouse Health, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Naturhouse Health's assets?
Raw Data
BATS-CHIXE:NTHe PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in EUR €0.27
BME:NTH Share Price * BME (2020-02-25) in EUR €1.47
United Kingdom of Great Britain and Northern Ireland Specialty Retail Industry PB Ratio Median Figure of 36 Publicly-Listed Specialty Retail Companies 0.61x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,323 Publicly-Listed Companies 1.11x
BATS-CHIXE:NTHe PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= BME:NTH Share Price ÷ Book Value per Share (both in EUR)

= 1.47 ÷ 0.27

5.36x

* Primary Listing of Naturhouse Health.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Naturhouse Health is overvalued based on assets compared to the GB Specialty Retail industry average.
X
Value checks
We assess Naturhouse Health's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Specialty Retail industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Specialty Retail industry average (and greater than 0)? (1 check)
  5. Naturhouse Health has a total score of 4/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Naturhouse Health expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Naturhouse Health has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
15.7%
Expected Specialty Retail industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Naturhouse Health expected to grow at an attractive rate?
  • Unable to compare Naturhouse Health's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Naturhouse Health's earnings growth to the United Kingdom of Great Britain and Northern Ireland market average as no estimate data is available.
  • Unable to compare Naturhouse Health's revenue growth to the United Kingdom of Great Britain and Northern Ireland market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
BATS-CHIXE:NTHe Future Growth Rates Data Sources
Data Point Source Value (per year)
United Kingdom of Great Britain and Northern Ireland Specialty Retail Industry Earnings Growth Rate Market Cap Weighted Average 15.7%
United Kingdom of Great Britain and Northern Ireland Specialty Retail Industry Revenue Growth Rate Market Cap Weighted Average 3.7%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 15.5%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 2.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BATS-CHIXE:NTHe Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BATS-CHIXE:NTHe Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
BATS-CHIXE:NTHe Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-12-31 82 20 13
2019-09-30 83 13
2019-06-30 83 18 13
2019-03-31 85 15
2018-12-31 87 20 15
2018-09-30 88 16
2018-06-30 91 19 17
2018-03-31 93 18
2017-12-31 95 16 20
2017-09-30 96 21
2017-06-30 98 15 22
2017-03-31 98 22

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Naturhouse Health is high growth as no earnings estimate data is available.
  • Unable to determine if Naturhouse Health is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BATS-CHIXE:NTHe Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Naturhouse Health Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:NTHe Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
BATS-CHIXE:NTHe Past Financials Data
Date (Data in EUR Millions) EPS *
2019-12-31 0.22
2019-09-30
2019-06-30 0.21
2019-03-31
2018-12-31 0.26
2018-09-30
2018-06-30 0.29
2018-03-31
2017-12-31 0.33
2017-09-30
2017-06-30 0.37
2017-03-31

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Naturhouse Health will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine whether Naturhouse Health is trading at Naturhouse Health'san attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  2. Naturhouse Health's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Retail companies here
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Naturhouse Health's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Naturhouse Health has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Naturhouse Health performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Naturhouse Health's growth in the last year to its industry (Specialty Retail).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Naturhouse Health's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
  • Naturhouse Health's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Naturhouse Health's 1-year earnings growth is negative, it can't be compared to the GB Specialty Retail industry average.
Earnings and Revenue History
Naturhouse Health's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Naturhouse Health Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:NTHe Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 81.67 13.26 26.64
2019-09-30 83.12 13.30 30.32
2019-06-30 82.96 12.68 30.33
2019-03-31 85.35 14.58 30.70
2018-12-31 87.29 15.37 31.10
2018-09-30 88.46 15.95 30.92
2018-06-30 90.86 17.35 30.80
2018-03-31 93.12 18.45 30.81
2017-12-31 94.70 19.86 30.31
2017-09-30 96.32 21.35 29.21
2017-06-30 97.60 22.03 28.86
2017-03-31 97.97 22.32 28.70
2016-12-31 97.82 22.50 28.30
2016-09-30 98.29 23.05 27.40
2016-06-30 97.74 23.50 27.36
2016-03-31 96.39 23.09 27.02
2015-12-31 95.79 22.86 27.09
2015-09-30 95.77 22.80 26.98
2015-06-30 95.91 22.87 26.82
2015-03-31 96.08 23.20 26.53
2014-12-31 95.73 22.56 25.88
2013-12-31 59.88 8.54 19.50

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Naturhouse Health made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%).
  • Naturhouse Health used its assets more efficiently than the GB Specialty Retail industry average last year based on Return on Assets.
  • Naturhouse Health's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Naturhouse Health's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Specialty Retail industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Naturhouse Health has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Naturhouse Health's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Naturhouse Health's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Naturhouse Health is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Naturhouse Health's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Naturhouse Health's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 8.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Naturhouse Health Company Filings, last reported 3 months ago.

BATS-CHIXE:NTHe Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 16.51 2.73 10.31
2019-09-30 18.59 11.39 12.03
2019-06-30 19.50 2.75 18.90
2019-03-31 23.36 11.47 16.10
2018-12-31 18.84 2.87 8.25
2018-09-30 20.53 3.05 11.39
2018-06-30 27.88 2.99 18.71
2018-03-31 29.20 3.09 16.41
2017-12-31 24.50 3.10 8.33
2017-09-30 22.34 3.35 12.33
2017-06-30 30.12 3.22 20.47
2017-03-31 33.22 3.18 21.91
2016-12-31 27.15 3.16 16.13
2016-09-30 23.82 3.24 20.76
2016-06-30 30.75 3.39 29.20
2016-03-31 27.46 4.33 25.97
2015-12-31 22.02 4.76 19.87
2015-09-30 18.17 5.81 15.90
2015-06-30 15.88 6.15 17.71
2015-03-31 8.39 7.47 9.28
2014-12-31 15.37 8.71 19.71
2013-12-31 12.61 20.55 31.03
  • Naturhouse Health's level of debt (16.5%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (56.9% vs 16.5% today).
  • Debt is well covered by operating cash flow (720.5%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 150.7x coverage).
X
Financial health checks
We assess Naturhouse Health's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Naturhouse Health has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Naturhouse Health's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
17.01%
Current annual income from Naturhouse Health dividends.
If you bought €2,000 of Naturhouse Health shares you are expected to receive €340 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Naturhouse Health's pays a higher dividend yield than the bottom 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (2.59%).
  • Naturhouse Health's dividend is above the markets top 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (7.08%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BATS-CHIXE:NTHe Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
United Kingdom of Great Britain and Northern Ireland Specialty Retail Industry Average Dividend Yield Market Cap Weighted Average of 22 Stocks 4.7%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 588 Stocks 5.6%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1.3%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 2.6%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 7.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BATS-CHIXE:NTHe Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
BATS-CHIXE:NTHe Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2020-03-02 0.250 15.960
2020-02-28 0.250 11.213
2019-04-29 0.280 13.643
2019-03-01 0.280 12.267
2019-02-28 0.280 11.619
2018-03-05 0.320 11.368
2017-02-28 0.380 8.753
2016-02-26 0.320 7.101

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Whilst dividend payments have been stable, Naturhouse Health has been paying a dividend for less than 10 years.
  • Naturhouse Health has only been paying a dividend for 4 years, and since then dividends per share have fallen.
Current Payout to shareholders
What portion of Naturhouse Health's earnings are paid to the shareholders as a dividend.
  • Dividends paid are not well covered by earnings (0.9x coverage).
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Naturhouse Health's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Naturhouse Health afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Naturhouse Health has a total score of 2/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Naturhouse Health's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Félix Revuelta Fernández
COMPENSATION €1,337,000
CEO Bio

Mr. Felix Revuelta Fernandez serves as President of Spanish Kiluva group, the holding company for Naturhouse. Mr. Revuelta Fernandez serves as Chairman and Chief Executive Officer at Kiluva, S.A. He serves as the Executive Chairman and Chief Executive Officer of Naturhouse Health, S.A. He serves as Joint Administrator at Housediet, S.L.U and Laboratorios Abad. He is employed at Kiluva Portuguesa Nutriçao e Dietetica, Lda; Zamoglas, S.A.; Girofibra; Nutraceutical Corp. He worked at the Spanish National Industrial Institute and as a Consultant. He is Chair of Naturhouse SARL ; Naturhouse SRL; Housediet Llc; Zamodiet de Mexico, S.A.; HO, SARL; NH Franchising Co, Ltd. and NH SPRL (Belg). He served as a Vice Chairman of Natraceutical SA since March 31, 2011 until December 30, 2014 and its Director since February 21, 2008 until December 30, 2014. He has been Director of Naturhouse Health, S.A. since October 2, 2014. He serves as a Director at Kiluva Diet, S.L.U; Naturhouse SP Zoo; Naturhouse Gmbh; Zamodiet, S.A.; Gartabo, S.A ; Ichem, SP Zoo and Sniace, S.A. He served as Director at DIETISA (the Spanish subsidiary of Dietetique et Santé). Mr. Revuelta Fernandez is an Economist.

CEO Compensation
  • Félix's compensation has increased by more than 20% in the past year whilst earnings fell less than 20%.
  • Félix's remuneration is lower than average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team

Félix Revuelta Fernández

TITLE
Executive Chairman & CEO
COMPENSATION
€1M

Vanesa Revuelta Rodríguez

TITLE
Executive Vice Chairman
COMPENSATION
€334K

Kilian Revuelta Rodríguez

TITLE
Executive Vice Chairman
COMPENSATION
€334K

Hugo Campillo

TITLE
Chief Financial Officer
TENURE
6.3 yrs
Board of Directors Tenure

Average tenure and age of the Naturhouse Health board of directors in years:

5.5
Average Tenure
75
Average Age
  • The tenure for the Naturhouse Health board of directors is about average.
Board of Directors

Félix Revuelta Fernández

TITLE
Executive Chairman & CEO
COMPENSATION
€1M

Vanesa Revuelta Rodríguez

TITLE
Executive Vice Chairman
COMPENSATION
€334K

Kilian Revuelta Rodríguez

TITLE
Executive Vice Chairman
COMPENSATION
€334K

Pedro Nueno Iniesta

TITLE
Non-Executive Independent Director
COMPENSATION
€30K
AGE
75
TENURE
5.5 yrs

José María Castellano Ríos

TITLE
Independent Director
COMPENSATION
€42K
AGE
72
TENURE
5.5 yrs

Rafael Moreno Barquero

TITLE
Proprietary Director
COMPENSATION
€99K
TENURE
5.5 yrs

Ignacio Bayón Mariné

TITLE
Independent Director
AGE
75
TENURE
3.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
27. Jan 20 Buy Kiluva S.A. Company 22. Jan 20 24. Jan 20 17,075 €2.12 €35,969
21. Jan 20 Buy Kiluva S.A. Company 16. Jan 20 20. Jan 20 18,000 €2.10 €37,449
16. Jan 20 Buy Kiluva S.A. Company 13. Jan 20 15. Jan 20 23,900 €2.05 €48,766
04. Oct 19 Buy Kiluva S.A. Company 01. Oct 19 03. Oct 19 4,199 €1.92 €8,058
27. Nov 19 Buy Kiluva S.A. Company 27. Nov 19 27. Nov 19 8,645 €2.13 €18,401
25. Sep 19 Buy Kiluva S.A. Company 19. Sep 19 24. Sep 19 7,536 €1.96 €14,635
23. Dec 19 Buy Kiluva S.A. Company 19. Dec 19 23. Dec 19 17,240 €2.02 €34,627
03. Dec 19 Buy Kiluva S.A. Company 28. Nov 19 02. Dec 19 16,900 €2.12 €35,076
07. Oct 19 Buy Kiluva S.A. Company 04. Oct 19 04. Oct 19 318 €1.94 €617
13. Dec 19 Buy Kiluva S.A. Company 10. Dec 19 13. Dec 19 22,100 €2.10 €45,300
22. Nov 19 Buy Kiluva S.A. Company 18. Nov 19 19. Nov 19 5,141 €2.04 €10,464
12. Nov 19 Buy Kiluva S.A. Company 06. Nov 19 11. Nov 19 7,201 €1.95 €13,856
01. Oct 19 Buy Kiluva S.A. Company 25. Sep 19 30. Sep 19 8,364 €1.93 €16,088
19. Dec 19 Buy Kiluva S.A. Company 16. Dec 19 18. Dec 19 23,142 €2.02 €46,462
15. Nov 19 Buy Kiluva S.A. Company 12. Nov 19 14. Nov 19 12,420 €1.96 €24,030
10. Dec 19 Buy Kiluva S.A. Company 03. Dec 19 09. Dec 19 11,383 €2.14 €23,289
08. Jan 20 Buy Kiluva S.A. Company 27. Dec 19 06. Jan 20 25,095 €2.07 €50,985
01. Oct 19 Buy Kilian Revuelta Rodríguez Individual 25. Sep 19 25. Sep 19 500 €1.92 €960
26. Sep 19 Buy Kilian Revuelta Rodríguez Individual 15. Aug 19 25. Sep 19 600 €2.14 €1,184
19. Sep 19 Buy Félix Revuelta Fernández Individual 16. Sep 19 18. Sep 19 6,298 €1.98 €12,351
17. Sep 19 Buy Félix Revuelta Fernández Individual 10. Sep 19 12. Sep 19 6,200 €2.03 €12,476
10. Sep 19 Buy Félix Revuelta Fernández Individual 05. Sep 19 09. Sep 19 4,692 €2.03 €9,469
05. Sep 19 Buy Félix Revuelta Fernández Individual 04. Sep 19 04. Sep 19 6,128 €2.01 €12,233
02. Sep 19 Buy Félix Revuelta Fernández Individual 30. Aug 19 30. Aug 19 3,018 €2.00 €5,986
28. Aug 19 Buy Félix Revuelta Fernández Individual 20. Aug 19 20. Aug 19 2,500 €1.98 €4,950
26. Aug 19 Buy Félix Revuelta Fernández Individual 22. Aug 19 22. Aug 19 4,804 €1.99 €9,492
16. Aug 19 Buy Félix Revuelta Fernández Individual 09. Aug 19 14. Aug 19 7,171 €2.02 €14,339
12. Aug 19 Buy Félix Revuelta Fernández Individual 06. Aug 19 08. Aug 19 5,295 €1.99 €10,503
05. Aug 19 Buy Félix Revuelta Fernández Individual 31. Jul 19 02. Aug 19 9,500 €1.95 €18,492
02. Jul 19 Buy Félix Revuelta Fernández Individual 27. Jun 19 27. Jun 19 2,000 €2.11 €4,205
26. Jun 19 Buy Félix Revuelta Fernández Individual 21. Jun 19 21. Jun 19 1,828 €2.10 €3,839
21. Jun 19 Buy Félix Revuelta Fernández Individual 17. Jun 19 19. Jun 19 7,900 €2.12 €16,635
18. Jun 19 Buy Félix Revuelta Fernández Individual 12. Jun 19 14. Jun 19 5,790 €2.10 €12,113
13. Jun 19 Sell Rafael Moreno Barquero Individual 11. Jun 19 12. Jun 19 -15,000 €2.10 €-31,295
12. Jun 19 Buy Félix Revuelta Fernández Individual 07. Jun 19 11. Jun 19 7,914 €2.10 €16,634
12. Jun 19 Sell Rafael Moreno Barquero Individual 30. May 19 07. Jun 19 -30,000 €2.10 €-62,279
10. Jun 19 Sell Rafael Moreno Barquero Individual 30. May 19 07. Jun 19 -30,000 €2.10 €-61,983
31. May 19 Buy Félix Revuelta Fernández Individual 29. May 19 31. May 19 9,743 €2.19 €20,973
28. May 19 Buy Félix Revuelta Fernández Individual 21. May 19 24. May 19 7,123 €2.21 €15,641
21. May 19 Buy Félix Revuelta Fernández Individual 15. May 19 20. May 19 14,100 €2.23 €31,333
16. May 19 Buy Félix Revuelta Fernández Individual 09. May 19 14. May 19 13,100 €2.37 €30,350
07. May 19 Buy Félix Revuelta Fernández Individual 30. Apr 19 06. May 19 270,579 €2.38 €643,269
X
Management checks
We assess Naturhouse Health's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Naturhouse Health has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Naturhouse Health, S.A. operates in the nutrition and weight management industry in Spain and internationally. The company sells food supplements that are made from natural extracts to facilitate the consumption of various nutrients; and foods and drinks, such as diet products for breakfast, snacks, and meal substitutes. It also offers cosmetics and body care products, including beauty products related to skincare during the slimming process comprising cellulite, firming products, etc.; and anti-ageing products. The company sells its products through directly-operated or franchise Naturhouse centers. It operates approximately 2,400 centers in 33 countries. The company was formerly known as Housediet, S.L.U. The company was founded in 1991 and is based in Madrid, Spain.

Details
Name: Naturhouse Health, S.A.
NTHe
Exchange: BATS-CHIXE
Founded: 1991
€88,125,735
59,949,480
Website: http://www.naturhouse.com
Address: Naturhouse Health, S.A.
Calle Claudio Coello 91,
4º Planta,
Madrid,
Madrid, 28006,
Spain
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
BME NTH Common Shares Bolsas y Mercados Espanoles ES EUR 24. Apr 2015
DB 2NH Common Shares Deutsche Boerse AG DE EUR 24. Apr 2015
LSE 0R9G Common Shares London Stock Exchange GB EUR 24. Apr 2015
BATS-CHIXE NTHe Common Shares BATS 'Chi-X Europe' GB EUR 24. Apr 2015
Number of employees
Current staff
Staff numbers
595
Naturhouse Health employees.
Industry
Specialty Stores
Retail
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/07 23:12
End of day share price update: 2020/02/25 00:00
Last estimates confirmation: 2019/02/28
Last earnings filing: 2020/03/02
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.